termsTerm
EGFR exon 19 deletion & L858R
Exon 19 deletion and L858R are the two common EGFR mutations, together ~85% of EGFR-mutant lung cancer, and both respond to EGFR pills.
Exon 19 deletions (~45%) respond somewhat better than L858R (~40%) to osimertinib; both are covered by first-line osimertinib, amivantamab-lazertinib, and osimertinib-chemotherapy. Uncommon mutations (G719X, L861Q, S768I) respond to afatinib; exon 20 insertions need amivantamab or sunvozertinib.
Genomics: what this kind of term is about · animated schematic, not to scale
Category
Genomics
cancers
1targets
1drugs
5ApprovedBispecific antibody (EGFR×MET)
Amivantamab · Rybrevant
Not mapped hereSmall-molecule EGFR TKI (first generation, reversible)
Erlotinib · Tarceva
Not mapped hereSmall-molecule EGFR TKI (first generation, reversible)
Gefitinib · Iressa
ApprovedSmall-molecule kinase inhibitor (EGFR)
Lazertinib · Lazcluze
ApprovedSmall-molecule kinase inhibitor (EGFR)
Osimertinib · Tagrisso